Coinsurance would disrupt the ability of health care practitioners to work with their patients to ascertain the best lab tests to help best diagnose new conditions, manage existing conditions, and guide therapy, which is critical for the Medicare population as they often have multiple comorbidities. Currently, since there is no cost-sharing, patients who need more…
Coinsurance would disrupt the ability of health care practitioners to work with their patients to ascertain the best lab tests to help best diagnose new conditions, manage existing conditions, and guide therapy, which is critical for the Medicare population as they often have multiple comorbidities. Currently, since there is no cost-sharing, patients who need more lab tests due to more complicated health conditions have no greater financial risk than patients those with less complex conditions when receiving their lab results – and a patient may not know whether their condition is simple or complex when they first see a doctor. Despite this common-sense approach, some policy-makers calling for entitlement reform and deficit reduction have proposed putting into place a new 20% patient coinsurance for clinical laboratory services as an attempt to make Medicare beneficiaries more aware of health care costs. In real life, coinsurance for lab services will dis-incentivize Medicare beneficiaries from receiving timely and life-saving clinical lab tests, thus increasing health care costs through worse outcomes, and would drastically increase the cost of providing lab services through generating millions of new patient bills.
-
ACLA NGS NCD comments
-
ACLA Applauds CMS for Removing Burdensome and Duplicative Medicare Advantage Compliance Training Requirements
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) today submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the 2019 Medicare ... Read More -
ACLA Comments on Medicare Compliance Training Requirements Proposed Rule
-
CMS Ignored Congressional Intent in Implementing New Clinical Lab Payment System Under PAMA, ACLA Charges in Suit
(Washington, D.C.) – The government agency that runs the Medicare program failed to follow a congressional directive to implement a market-based laboratory payment system, thereby ... Read More -
ACLA to CMS: Overall Finalized Rates Still Fundamentally Flawed, Agency Must Halt Implementation
(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) stepped up its call to the Centers for Medicare & Medicaid Services (CMS) to delay its ... Read More -
Laboratory Market Stakeholders Call for Suspension of Draft PAMA Rates; Urge CMS to Take Immediate Action to Address Flawed Data Collection and Methodology
ACLA, NILA, AdvaMedDx and POCTA Issue Joint Release Echoing Stakeholder Letter to Administrator Verma WASHINGTON, D.C. – Leading laboratory stakeholders in a joint letter to Centers ... Read More -
ACLA Unveils New Economic Analysis that Underscores Clinical Laboratory Industry’s Contribution to National, State, Local Jobs and Tax Base
Proposed Medicare Cuts to Clinical Lab Services May Cause Lab Closures, Job Losses, and Reduce Patient Access (Washington, D.C.) – The American Clinical Laboratory Association ... Read More -
ACLA Comments on Bucshon-DeGette Discussion Draft Impacting the Regulation of Clinical Laboratory Diagnostics
(Washington, D.C.) – Today, the American Clinical Laboratory Association (ACLA) submitted comments in response to a discussion draft, the Diagnostic Accuracy and Innovation Act (DAIA), ... Read More -
ACLA Letter to HHS OIG on Laboratory Recomendations in the 2016 Compendium of Unimplemented Recommendations
-
ACLA Commends House Appropriations Committee for Including Language in Agriculture-FDA Spending Bill Report Directing FDA To Suspend Draft Guidance to Regulate LDTs
WASHINGTON, D.C. – The American Clinical Laboratory Association (ACLA) today applauded House Appropriations Committee Chairman Harold Rogers, R-KY and Subcommittee Chairman Robert B. Aderholt, R-AL, ... Read More